A prospective validation of nomograms based on BC-116 and BC-106 1 urine peptide biomarker panels for bladder cancer diagnostics and 2 monitoring 3 4 Lourdes Mengual^{1,2}, Maria Frantzi³, Marika Mokou³, Mercedes Ingelmo-Torres¹, 5 Michiel Vlaming⁴, Axel S. Merseburger⁵, Marie C. Roesch⁵, Zoran Culig⁶, Antonio 6 Alcaraz¹, Antonia Vlahou⁷, Harald Mischak^{3,8} and Antoine G. Van der Heijden⁴ 7 8 ¹Laboratory and Department of Urology, Hospital Clinic de Barcelona, Institut 9 d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centre de Recerca 10 Biomèdica CELLEX, Universitat de Barcelona, Barcelona, Spain; 11 ²Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, 12 University of Barcelona, Barcelona, Spain; 13 ³Department of Biomarker Research, Mosaigues Diagnostics, Hannover, Germany; 14 15 ⁴Department of Urology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands: 16 ⁵University Hospital Schleswig-Holstein, Campus Lübeck, Department of Urology, 17 Lübeck: Germany: 18 ⁶Experimental Urology, Department of Urology, Medical University of Innsbruck, 19 Innsbruck, Austria; 20 ⁷Systems Biology Center, Biomedical Research Foundation, Academy of Athens, 21 Athens, Greece; 22 ⁸Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK. 23 24 25 Running title: Prospective validation of nomograms based on BC-116 & BC-106 26 Keywords: Biomarker, Bladder Cancer, Diagnosis, Mass Spectrometry, Urine. 27 28 **Financial Support:** 29 30 This work was supported by BioMedBC (752755; H2020-MSCA-IF-2016), funded by the 31 European Commission. 32 33

It is made available under a CC-BY-NC-ND 4.0 International license .

34 Corresponding author:

35 Dr. Maria Frantzi, Mosaiques Diagnostics GmbH, Rotenburger Strasse 20, Hannover D-

36 **30659**, Germany; Phone: 0049 51155474429; Fax: 0049 51155474431; E-mail:

37 frantzi@mosaiques-diagnostics.com

38

39 **Conflict of interest:**

H.M. holds ownership interest in Mosaiques Diagnostics GmbH. M.F. and M.M. are
employed by Mosaiques Diagnostics GmbH. No potential conflicts of interest were
disclosed by the other authors.

43

44 **Notes:**

45 Word count: 4456 (main text)

46 Total number of Figures: 5

47 Total number of Tables: 1

48

49 Translational Relevance (150- max. 150 words)

50 Bladder cancer (BC) has the highest lifetime cost per patient among all cancers due to 51 the high recurrence rate and the need for a long-term patient monitoring. Several 52 urinary biomarkers have been identified in recent years for BC detection and monitoring. 53 However, reaching a diagnostic accuracy sufficient for clinical implementation is challenging. A pilot comparison showed complementarity between cytology and two 54 55 previously reported urinary biomarker panels for BC detection (BC-116) and surveillance (BC-106). Considering this hypothesis, here we present a prospective 56 57 multicenter study aiming to evaluate diagnostic nomograms integrating cytology and the biomarker panels in 602 patients screened for primary and recurrent BC. Overall, the 58 59 nomogram including cytology and BC-116 panel demonstrated good performance but 60 similar to BC-116 alone, in primary BC detection. Notably, the nomogram including BC-61 106 panel and cytology showed added value and could be potentially applied for BC surveillance by reducing the average number of follow-up cystoscopies. 62

- 63
- 64
- 65
- 66
- 67

It is made available under a CC-BY-NC-ND 4.0 International license .

68 Abstract (250/250 words)

69

Purpose: Non-invasive urine-based biomarkers for bladder cancer (BC) diagnosis and surveillance can potentially improve current diagnostic and monitoring protocols by guiding cystoscopy. Here, we aim to access the diagnostic performance of nomograms based on published biomarker panels for BC detection (BC-116) and monitoring of recurrence (BC-106) in combination with cytology, in two prospectively collected patient cohorts.

76

Experimental Design: 602 recruited patients were screened for presence of BC, out of which 551 were found eligible for further analysis. For the primary setting, urine samples from 73 eligible patients were analyzed from those diagnosed with primary BC (n=27) and benign urological disorders (n=46). For the surveillance setting, 478 eligible patients were considered (83 BC recurrences; 395 negative for recurrence). Urine samples were analyzed with capillary electrophoresis coupled to mass spectrometry and the biomarker score was estimated via a support vector machine-based software.

84

85 **Results:** Validation of the BC-116 biomarker panel resulted in 89% sensitivity and 86 67% specificity (AUC_{BC-116}=0.82), similar to the published estimates. The nomogram 87 based on cytology and BC-116 resulted in good (AUC_{Nom116}=0.85) but not significantly better performance than the BC-116 alone (P=0.5672). BC-106 biomarker panel 88 89 showed 89% sensitivity and 32% specificity for surveillance, while improved performance was achieved when a nomogram including BC-106 and cytology was 90 evaluated significantly 91 $(AUC_{Nom106}=0.82),$ outperforming both cytology (AUC_{cvt}=0.72;P=0.0022) and BC-106 alone (AUC_{BC-106}=0.67;P=0.0012). 92

93

Conclusions: BC-116 biomarker panel is a useful test for detecting primary BC.
 BC-106 classifier integrated with cytology and showing >95% negative predictive value,
 might be useful for decreasing the number of cystoscopies during surveillance.

97

98

It is made available under a CC-BY-NC-ND 4.0 International license .

100 Introduction

101 Bladder cancer (BC) has the highest recurrence rate of all cancers. The overall lifetime risk for BC is 2.4%. In Europe, the age-standardized incidence and mortality rates for 102 103 BC are 11.3 and 3.0 per 100,000 person years, respectively (1,2). In the USA, the respective rate is 10.9 per 100,000 person years, while the annual number of 104 105 attributable deaths is 2.1 per 100,000 persons (2,3). Most incident BC cases (roughly 106 75%) are non-muscle invasive (NMIBC) tumors, exhibiting a 5-year recurrence rate of 107 50-70% and a 10-30% 5-year progression rate to muscle-invasive disease (MIBC), thus 108 necessitating long-term patient monitoring (4). Both the timely detection of primary/ 109 incident BC and efficacious surveillance of BC recurrence are vital for optimal patient outcomes. Cystoscopy remains the gold standard for BC detection (5). However, it is an 110 invasive and expensive approach, having also potential complications while subtle 111 recurrences can be easily missed (6). Furthermore, it is bothersome for patients (7). 112 During the corona pandemic, increased waiting times for cystoscopies, and delayed 113 diagnoses are more prominent. The European Association of Urology (EAU) (8) gives 114 priority to patients with high-risk tumors, whereas recommends postponing cystoscopy 115 116 by six months for patients with low and intermediate -risk tumors, which might be 117 stressful for a lot of patients. Urine cytology is still the most accurate non-invasive test 118 for BC detection having high sensitivity (84%) in high grade (G3) tumors, but low 119 sensitivity (16%) in low grade tumors (G1), while in experienced hands specificity can 120 reach values over 90% (5). However, in recent large prospective multicenter studies it was demonstrated that the performance of urine cytology in contemporary practice 121 proves to be even lower than previously reported (9). Thus, a clear need for a non-122 123 invasive approach for BC detection and monitoring is evident. Liquid biopsy has yielded 124 enormous interest in the field of BC (10) with urine being particularly attractive due to its 125 direct contact with the tumor as well as it can be easily collected in a non-invasive 126 manner (11).

127 Capillary electrophoresis coupled to Mass Spectrometry (CE-MS) provides high-128 resolution proteomics profiling data, is characterized by high reproducibility (12) and has 129 been applied for the investigation of peptides and low molecular weight proteins as 130 biomarkers derived from body fluids, especially urine (12,13). Candidate biomarkers can 131 be sequenced and identified by employing CE coupled to tandem MS (MS/MS) and 132 liquid chromatography coupled to MS/MS (LC-MS/MS) proteomics platforms (14), in

It is made available under a CC-BY-NC-ND 4.0 International license .

133 combination with appropriate bioinformatics tools and algorithms that enable CE-MS 134 data assessment, peptide list extraction and calibration using internal standard peptides 135 (15). Urinary profiling data acquired by CE-MS have been previously explored for detection of BC (16) as well as discrimination of NMIBC from MIBC (17). Moreover, 136 137 multi-biomarker panels appear advantageous compared to single biomarkers, especially 138 in the context of complex diseases (18). Towards the need for reducing cystoscopies, we previously developed two urinary peptide biomarker panels for: i) non-invasive 139 140 detection of primary BC (BC-116 biomarker panel) and ii) for monitoring of recurrent BC in patients undergoing surveillance (BC-106 biomarker panel) (19). To develop both 141 142 biomarker panels, in the above initial study a total of 1,357 urine samples from patients 143 suspected of BC, as well as non-malignant urological controls from five different clinical 144 centers were analyzed through CE-MS. Among the biomarkers were peptides of Small 145 proline-rich protein 3, 14-3-3 sigma protein, CD99 antigen, Apolipoprotein A-I, Fibrinogen α and β , Beta-2-macroglobulin, Basement membrane-specific heparan 146 147 sulfate proteoglycan core protein and Membrane-associated progesterone receptor 148 component 1. Both biomarker panels exhibited good performance, with the BC-116 149 biomarker panel reaching 91% sensitivity and 68% specificity, and the BC-106 150 biomarker panel 87% sensitivity and 51% specificity at the pre-defined threshold. The 151 area under the ROC curve values (AUCs) were 0.87 and 0.75, for detection of primary 152 (BC-116) and recurrent (BC-106) urothelial BC, respectively. When investigating the subpopulation of low/ intermediate-risk patients (NMIBC G1-G2), although in low 153 154 number of patients (n=26), BC-106 biomarker panel yielded a sensitivity of 89% in detecting recurrent BC (AUC=0.72). Additionally, the negative predictive value (NPV) 155 and positive predictive value (PPV) of BC-116 were estimated at 81.3% and 83.2% 156 (considering a prevalence rate of 63.5%), while for BC-106 at 93.6% and 32.3% 157 respectively (accounting for a prevalence of 21.2%) (19). The predictive value of BC-158 159 106 biomarker panel for BC relapse was also evaluated in a follow-up study indicating a 160 prognostic potential of the urinary biomarker panel based on the peptidomics profile in 161 prognosis of BC recurrence [HR: 3.15; 1.73-5.70 (95% CI); P=0.0002] (20).

Based on the above biomarker panels, a pilot assessment showed an added value of the urine biomarker panels when combined with cytology, and thus demonstrated a level of complementarity between the two urological investigations (19). Considering this hypothesis, here we present a multicenter clinical study with the aim to evaluate diagnostic nomograms based on cytology and the BC-116 and BC-106 peptide

It is made available under a CC-BY-NC-ND 4.0 International license .

biomarkers in a prospective setting. To this end, 602 patients were recruited, those with
 suspicious symptoms or under surveillance that were scheduled for cystoscopic
 examination to investigate presence of BC.

170

171 Materials and Methods

172 Study design and participants

In this study, 602 patients with suspicious symptoms for BC and those patients under 173 surveillance because of a previous BC diagnosis were enrolled at the Radboud 174 University Medical Center in Nijmegen (The Netherlands) and at the Hospital Clinic of 175 Barcelona (Spain). Out of the 602 patients, 18 were excluded due to the presence of 176 177 other cancers / comorbidities including: i) upper urinary tract cancer (n=14), ii) prostate cancer (n=2), iii) renal cell carcinoma (n=1) and iv) pancreatic carcinoma (n=1). Of the 178 179 remaining 584 patients, 33 initially defined as positive for BC (based on cystoscopy) were further excluded as histopathological data based on transurethral resection of the 180 181 bladder tumor (TURB-T) or biopsy were either not available or reported a benign lesion. 182 Therefore, the positive cystoscopy result could not be confirmed. Among the 551 183 eligible patients, 366 were recruited at the Hospital Clinic of Barcelona and 208 at the Radboud University Medical Center. For the biomarker panel validation, the patients 184 were stratified into two cohorts: a) the primary group including 73 patients positive for 185 primary BC and those with suspicious symptoms scheduled for cystoscopy, and b) the 186 187 recurrent group, including 478 patients under surveillance, as presented in detail below. 188 In all cases the presence of bladder tumors was confirmed with cystoscopy and 189 histological confirmation (biopsy or TURB-T). Tumor grade and stage were determined 190 according to WHO criteria (21) and Tumor Node Metastasis (TNM) classification (22), respectively. Tumors were classified according to their risk of recurrence and 191 192 progression into high, intermediate, or low risk based on the EAU guidelines published 193 in 2018 (23). The study was performed in accordance with the Declaration of Helsinki 194 and ethical approval was obtained by local Ethics Committees. Informed consent processes adhered to Institutional Review Board-approved guidelines. Ethical approval 195 for this study was obtained by the Ethics Committee in Medical School of Hannover (ID: 196 197 3274-2016). A schematic representation of the study design is presented in **Figure 1**.

198

It is made available under a CC-BY-NC-ND 4.0 International license .

200 **Primary cohort**

For assessing primary urothelial BC, 73 eligible participants, as per availability, were 201 202 evaluated. Forty- six patients were enrolled at the Hospital Clinic of Barcelona whereas 203 the remaining 27, were patients undergoing cystoscopy at Radboud University Medical 204 Center. Among the 73 patients, 27 were diagnosed with primary urothelial BC whereas 205 the remaining 46 presented with suspicious symptoms for BC, hematuria, or suffered from other urological diseases (e.g. acute cystitis, nephrolithiasis) and served as 206 207 urologic controls. At the time of recruitment all patients with primary tumors did not have 208 a prior history of urothelial cell carcinoma and underwent transurethral resection to 209 radically remove the bladder tumor. The cohort characteristics are summarized in **Table** 210 1 and the full list of patient clinical data is given in **Supplementary Table S1**.

211

212 **Recurrent cohort**

213 For the evaluation of BC recurrence, 511 patients scheduled for follow-up monitoring cystoscopies due to prior history of BC were analyzed in compliance with the EAU 214 215 guidelines and the European Organization for Research and Treatment of Cancer 216 (EORTC) recurrence and progression scores (23). Among these were 320 patients 217 undergoing cystoscopy at the Hospital Clinic of Barcelona and 181 at the Radboud 218 University Medical Center. In both clinical centers, BC recurrence was confirmed by 219 cystoscopy and histological assessment. Negative score at cystoscopy was used to 220 exclude recurrence and define controls. The recurrent cohort comprised of 83 confirmed 221 BC cases and 395 negative for recurrence controls. Of the 83 relapses, 79 were NMIBC (Ta, CIS, T1) and 4 MIBC (≥T2) cases. The cohort characteristics are summarized in 222 223 Table 1 and the full list of patient clinical data is given in Supplementary Table S2. 224 Complete information about the clinicopathological tumor characteristics (including risk, 225 stage, and grade) for the previously diagnosed BC tumors is also provided 226 (Supplementary table S2).

227

228 Urine collection and cytologic evaluation

All urine samples were collected prior to cystoscopy, if applicable the day before the TURB-T or the day before cystectomy. Voided urine samples were collected in sterile containers and immediately stored at -20°C until further processing. From all patients and controls, only one single sample was included. Without being mandatory, patients

It is made available under a CC-BY-NC-ND 4.0 International license .

were advised to have cytology at cystoscopy or during the period between cystoscopy and surgery. Urine cytology was performed according to Papanicolaou staining and evaluated by expert pathologists in each center blinded to the patient's clinical history.

The results were considered as positive or negative.

237

238 Sample preparation and CE-MS analysis

239 Urine sample preparation and CE-MS analysis was performed according to previous reports (19,20,24). In brief, 700 µl of each urine sample were diluted with two volumes 240 alkaline buffer containing $2 \square M$ urea, $10 \square mM$ NH₄OH and 0.02% SDS (pH 10.5). 241 242 Thereafter, the samples were concentrated at 1.1 ml using Centrisart ultracentrifugation 243 filters with a cut-off of 20 kDa (Sartorius, Göttingen, Germany) after centrifugation at 3,000g. The filtrate was then desalted using PD-10 columns (GE Healthcare, Munich, 244 Germany) and equilibrated in 0.01% NH₄OH in HPLC-grade water. The peptide extracts 245 were lyophilized and stored at 4°C until further use. CE-MS analysis was performed 246 247 using a P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Fullerton, 248 USA) on-line coupled to a MicroTOF MS (Bruker Daltonic, Bremen, Germany), as 249 described previously (19,20). Mass spectral ion peaks representing identical molecules 250 at different charge states were deconvoluted into single masses using MosaiguesVisu 251 software (25). In addition, migration time and ion signal intensity (amplitude) were 252 normalized using 29 internal peptide standards with excretion levels unaffected by any 253 disease state (26). The resulting peak list characterizes each peptide by its molecular 254 mass [kDa], normalized migration time [min], and normalized signal intensity. The 255 detected peptides were annotated, matched and deposited in a Microsoft SQL database 256 (Human Urinary Proteome Database (12,27)) and used as an input in the present study. 257 Accuracy, precision, selectivity, sensitivity, reproducibility, and stability were reported 258 previously (16,24).

259

260 Statistical Analysis

The proportion, mean, standard deviation, median and interquartile range (25th–75th percentiles) estimates were calculated to describe the distribution of the different variables in the patients' cohorts (summarized in **Table 1**). The biomarker panels' scores were calculated via the support vector machine (SVM)-based software, namely

It is made available under a CC-BY-NC-ND 4.0 International license .

265 MosaCluster (version 1.7.0), as previously described (19). Sensitivity and specificity of the biomarker panels were estimated based on the number of correctly classified 266 267 samples, as defined by cystoscopy. Confidence intervals (95% CI) were based on exact binomial calculations and were calculated along with the receiver operating 268 269 characteristic (ROC) plots in MedCalc® Version 12.1.0.0 (Mariakerke, Belgium). The 270 area under the ROC curve (AUC) was evaluated to estimate the overall accuracy 271 independent upon a particular threshold (28). The relationship of BC-116 and BC-106 272 panel with cytology was established using multiple linear regression analyses.

273

274 **Results**

275 Validation of the BC-116 biomarker panel for detection of primary BC

276 First, assessment of the BC-116 biomarker panel alone was performed to investigate its 277 significance for the BC detection. For the evaluation of the BC-116 biomarker panel, the 278 primary patient cohort was utilized, including 27 patients with primary urothelial BC and 279 46 patients presenting with non-malignant urological conditions. As shown in **Figure 2a**, the AUC for BC-116 biomarker panel (AUC_{BC-116}) was estimated at 0.82 with the 95% CI 280 ranging from 0.71 to 0.90 (P< 0.0001). At the validated cut-off level of -0.27, the 281 282 sensitivity was estimated at 89% and the specificity at 67%. The classifier correctly 283 classified 24 out of the 27 primary BC cases whereas 15 out of the 46 urological controls were misclassified as BC cases. Considering a prevalence rate of 37%, as 284 285 estimated on the basis of the participating centers, the NPV was computed at 91% 286 (95% CI 61% to 100%) while the PPV was estimated at 61% (95% CI 33% to 85%). As 287 presented in Figure 2B, the BC-116 biomarker panel significantly discriminated urothelial BC cases from controls (P<0.0001, Kruskal-Wallis H test) but also separated 288 controls from cases according to their TNM stage and grade (P< 0.05, Kruskal-Wallis H 289 test; Figure 2C-D). 290

291

292 **Comparative assessment of BC-116 with cytology**

For 58 (out of 73) patients of the primary cohort, data from the cytologic evaluation of the urine samples were available (**Supplementary Table 1**). Sensitivity of cytology for detecting primary BC was estimated at 42.3% while sensitivity of the classifier was 88.5% in this subset of patients. Twelve of the 26 primary BC cases were detected by the BC-116 biomarker panel but were missed by urine cytology. Notably, out of these 12

It is made available under a CC-BY-NC-ND 4.0 International license .

298 patients, eight were bearing low grade BC tumors (TaG1) but were also three patients 299 with high grade NMBC (T1G3) and one with MIBC that were missed by cytology and 300 detected by the BC-116. Three cases that were not detected by the BC-116 panel were 301 also missed by urine cytology. These were all patients bearing low grade BC (TaG1). 302 Along these lines, the NPV was higher for the BC-116 classifier (91.2%, 95% CI 60.9 – 303 99.7) than that of the urine cytology (73.2%, 95% CI 49 – 90.2). Nevertheless, PPV was higher for urine cytology (77.9%, 95% CI 26.7 – 99.2) than for the BC-116 classifier 304 (61.3%, 95% CI 31.4 - 86.0). Specificity of cytology was higher than that of the BC-116 305 panel (93.7% and 67.2% respectively). Multivariate analysis showed that BC-116 306 307 biomarker panel performed significantly better than cytology in primary BC detection, presenting an AUC value 0.84 (95% CI 0.72-0.92) for the classifier and 0.68 (95% CI 308 309 0.55-0.80) for cytology (P=0.0195 for pairwise comparison) (Figure 3A).

310

311 Integrative nomogram including BC-116 and cytology for detecting primary BC

- 312 An integrated nomogram based on the BC-116 based urinary biomarker panel and 313 cytology was also examined in the primary patient cohort. As shown in **Figure 3B**, the 314 AUC for the integrative nomogram was estimated 0.85 (0.73-0.93; 95% CI; P< 0.0001) 315 only slightly but not significantly higher than the BC-116 alone (0.84; P= 0.5672) yet 316 significantly higher than cytology alone (0.68; P= 0.0016). At the optimal cut-off level of 317 0.39, the sensitivity was estimated at 84.6% and the specificity at 75%. The integrative 318 nomogram correctly classified 23 out of the 26 primary BC cases whereas 9 out of the 319 32 controls were misclassified. Considering a prevalence rate of 37%, as estimated on 320 the basis of the participating centers, the NPV was computed at 89.5% (95% CI 60% to 321 99%) while PPV was estimated at 66.6% (95% CI 35% to 90%).
- 322

323 Validation of the BC-106 biomarker panel for detection of recurrent BC

324 The performance of the BC-106 biomarker panel for detection of bladder cancer 325 recurrence was evaluated in 478 patients. Among those, were 83 patients bearing a 326 histopathologically confirmed BC recurrence and 395 controls negative for recurrence. 327 As presented in Figure 4A, the AUC was estimated at 0.67 with the 95% CI ranging 328 from 0.63 to 0.72. At the previously established cut-off of -0.63, sensitivity was 329 estimated at 90.4% whereas specificity at 29.1%. This means that 75 out of the 83 330 recurrences were correctly classified as positive by the BC-106 biomarker panel. 331 However, the number of correctly classified negative controls was only 112. Accounting

It is made available under a CC-BY-NC-ND 4.0 International license .

for a prevalence of 17.4% in the investigated population, the NPV was estimated at 93.2% (95% CI 73.3% - 99.6%) while the PPV was calculated at 21.1% (95% CI 11.7% to 33.4%).

335

336 Comparison of BC-106 biomarker panel performance with urine cytology

337 Urine cytology was performed in 318 patients of which, based on cystoscopy, 36 were positive for recurrence cases and 282 were negative for recurrence controls. Sensitivity 338 339 of the BC-106 biomarker panel for detecting recurrent BC was higher than the one of cytology (91.6% and 50.0% respectively) in this subset of samples. However, the 340 specificity BC-106 biomarker panel was lower than the one of cytology (31.2% for the 341 342 classifier and 94.7% for cytology). Based on the ROC curve analysis, the estimated 343 AUCs were reported to be comparable between the two tests [AUC for BC-106 was 0.67 (0.61 to 0.72; 95% CI), while AUC for cytology was 0.72 (0.67 to 0.77; P for 344 difference between the 2 tests =0.3853), (**Figure 4B**). 345

346

347 Integrative nomogram including BC-106 and cytology for detecting recurrent BC

348 An integrative nomogram based on the BC-106 biomarker panel and cytology was 349 further validated in 318 patients from the recurrence cohort, for which the results from 350 the cytological examination were available. An improved diagnostic performance was 351 observed when the BC-106 classifier was integrated with urine cytology (AUC = 0.82, 352 95% CI 0.77-0.86, P< 0.0001), Figure 5A. At the optimal cut-off of 0.06, sensitivity was 353 estimated at 86% whereas specificity at 61%. Out of the 36 recurrent BC cases, 31 354 were correctly classified as positive by the integrative nomogram and out of 282, 172 355 patients were correctly classified as controls (negative for recurrence). Accounting for a prevalence of 17.4% in the investigated population, the NPV was estimated at 95.4% 356 (95% CI 74.9% - 99.9%) while the PPV was calculated at 31.7% (95% CI 11.3% to 357 358 59.1%). The nomogram was found of significantly improved performance in comparison 359 to cytology alone [AUC_{NOM106} was 0.74 (0.69 to 0.78; 95% CI) while AUC for cytology was 0.72 (0.67 to 0.77; P=0,0022)], but also compared to the BC-106 biomarker panel 360 361 alone [AUC for BC-106 was 0.66 (0.61 to 0.72; 95% CI; P= 0.0012)]. As presented in 362 Figure 5B, the integrative nomogram significantly discriminated recurrent BC cases 363 from negative for recurrence controls (P= 0.0005, Kruskal-Wallis H test), but also 364 separated patients with recurrent BC from those negative for recurrence (controls) according to their TNM stage and grade (P< 0.05, Kruskal-Wallis H test; Figure 5C-D). 365

It is made available under a CC-BY-NC-ND 4.0 International license .

366

Reducing the number of follow-up cystoscopies by using the Nomogram BC-106/ cytology

369 In the participating clinical centers of the study, recurrence was detected in 15.6% of all 370 follow-up cystoscopies while 84% of the patients previously diagnosed with BC were 371 without recurrence at the time of follow-up cystoscopy. At the cutoff point value of 0.06 of the integrative nomogram sensitivity was 86% whereas specificity at 61%. With a 372 373 very high NPV value (estimated at 95.4%) based on the nomogram, 172 out of 282 patients truly did not bear any recurrence, while only 4 out of the 36 cases would have 374 375 been missed. All four patients were carrying a low grade BC (TaG1). Based on this, and 376 assuming that patients who present a negative classification based on the integrative 377 nomogram (n=172) will not undergo a cystoscopy, more 60% of all cystoscopies could 378 be prevented, at the cost of 14% of low grade recurrences remaining undiagnosed.

379

380 Discussion

381 Within the last decade several urinary biomarkers have been developed for BC 382 detection and monitoring (summarized in (29,30)), including among others various 383 promising proteomics and peptidomics biomarkers identified by mass spectrometry (31). 384 To date, none of these biomarkers have replaced cystoscopy as the gold standard for 385 diagnosis and surveillance or has been accepted for diagnosis or follow-up in routine 386 practice or clinical guidelines (5,28). The lack of validation studies presents a challenge 387 in the expanding field of urinary biomarkers, thus delaying their uptake in the clinical 388 setting. In the present prospective study two unique urinary peptide-based biomarker 389 panels that were previously developed for detecting primary (BC-116 panel) and 390 recurrent urothelial BC (BC-106) based on CE-MS proteomics analyses (19) were 391 prospectively validated.

The BC-116 biomarker panel initially developed for detection of primary BC (19) demonstrated excellent reproducibility in this prospective cohort study. BC-116 exhibited good performance (AUC_{BC-116} 0.82) that was comparable to the one previously described (AUC 0.87) (19). Furthermore, BC-116 sensitivity and specificity (89% and 67% respectively) were similar to those previously reported (91% sensitivity and 68% specificity) (19). In this prospective study, BC-116 again performed better than cytology

It is made available under a CC-BY-NC-ND 4.0 International license .

398 and successfully classified the majority of the BC cases (panel: 24/27 patients; cytology: 399 11/27 patients). Cytology missed 58% of the tumors, similarly to other studies (32) and 400 did not identify any BC cases that were not previously identified by the BC-116 401 classifier. Interestingly, 82% of the cases that were missed by cytology were correctly 402 classified by the panel, while three cases that were missed by BC-116 were all low 403 grade BC. The negative predictive value of the classifier was also higher than cytology's 404 (91% versus 73%). Additionally, an integrative nomogram including BC-116 and cytology was investigated, showing, however only slightly increased performance over 405 406 the BC-116 alone. These results provide a strong argument for using BC-116 instead of 407 cytology. Considering that CE-MS is validated platform that is applied for routine 408 diagnostics, BC-116 biomarker panel could be potentially applied in clinical practice 409 even as an adjunct to cystoscopy to detect primary or missed tumors. Yet, a cost-410 effectiveness analysis is required to demonstrate economic efficiency.

For detection of recurrence, the BC-106 panel exhibited similar performance than urine 411 cytology, lower than previously reported (19). The observed reduced performance is 412 413 mostly attributed to the misclassification of almost half of the negative for recurrence 414 patients. The reduced specificity of BC-106 for detecting recurrent BC could be 415 attributed to differences in the study population and the demographics of the patients. In 416 the initial study, patients with a minimum of one year recurrence- free follow up were 417 investigated, while in this prospective setting, any patient during the regular BC 418 monitoring setting was included, mainly NMIBC (>98%). Importantly, BC-106 showed 419 complementary value with cytology. This fact was already previously observed and has 420 now been replicated in this study. Based on this, the previously reported integrative 421 nomogram including BC-106 and cytology, was also assessed, demonstrating 422 significantly increased performance compared to both cytology alone and the BC-106 423 alone.

Based on the performance estimates, accounting for NPV values of >90% for primary and >95% for surveillance, the availability of highly sensitive urine peptide markers, in combination with cytology allows for the reduction of the number of follow-up cystoscopies as in the clinical practice only patients with a positive test will undergo cystoscopy, whereas for those with a negative test cystoscopy could be postponed/ skipped (33). The integrative nomogram, including BC-106 classifier and cytology, ruled out 172 of the 282 samples, theoretically reducing the number of follow up cystoscopies

It is made available under a CC-BY-NC-ND 4.0 International license .

by factor 2. Based on the integrative BC-106 model, approximately 14% of the BC patients at follow-up were incorrectly misclassified as not having recurrence, but these were all low grade recurrent BC. Yet, even cystoscopy which is the gold standard misses up to 15% of the papillary and up to 30% of the flat lesions (34). These findings along with the high NPV of the integrative nomogram further supports that a voided urine sample can rule out BC with high confidence; thus reducing the number of cystoscopies and minimizing patients' discomfort.

438 Both BC-116 and BC-106 have similar performance as other FDA-approved and/or 439 currently under investigation urinary tests. To date, there are six urinary tests approved 440 by the FDA for clinical use in conjunction with cystoscopy (29,30). Among these, 441 NMP22 Bladder Cancer ELISA test, NMP22 BladderChek point-of-care test and 442 UroVysion have FDA approval for diagnosis and surveillance whereas immunocyte 443 (UCyt+), BTA-TRAK, and BTA-STAT have been approved for BC surveillance following the diagnosis of a primary tumor (29). Several meta-analyses studies have been 444 445 conducted to evaluate the performance of these panels and a remarkably broad 446 variation in the range of the sensitivity, specificity, NPV and PPV has been observed 447 (30). For instance, in a meta-analysis study of NMP22 BladderChek it was shown that 448 for detecting BC, the pooled sensitivity of the test was 56%, specificity was 88% and the 449 AUC value was 0.83 (35). Similarly, in another study evaluating the utility of UroVysion, 450 it was shown that the overall sensitivity, specificity, PPV, and NPV in detecting BC were 451 61.9%, 89.7%, 53.9%, and 92.4%, respectively (36). The performance rates of BC-116 452 and BC-106 panels are at least as good as the FDA-approved tests. However, 453 considering potential confounding factors and the significant variations in the clinical 454 setting, a direct comparison of our biomarkers with the FDA-approved based on the 455 data currently available is complicated and difficult to be accomplished.

456 A high NPV is important when the panel has a negative score and represents a point of 457 reference to spare unnecessary cystoscopies. This value is critical especially in high-458 grade disease where a negative biomarker test could result in a missed cancer, thus 459 having detrimental effects with respect to disease progression (30). In the present 460 study, the layout of the clinical settings closely represents a "real-clinical setting" 461 situation. Considering the prevalence rate of each cohort in this study, the NPV was 462 computed at 89.5% for the integrative nomogram of BC-116 classifier and cytology for 463 detecting primary BC and at 95.4% for the integrative nomogram of BC-106 and cytology for detecting BC recurrence, comparable to the previous study (19). Thus, both 464

It is made available under a CC-BY-NC-ND 4.0 International license .

panels demonstrated high NPV values that may offer benefit to patients with high-risk
disease (either with hematuria at primary diagnosis or under surveillance).

467 One of the limitations of this study is that potential confounding factors such as clinical 468 treatments before the last recurrence were not available for all patients and thus were 469 not considered. Nevertheless, as shown in the initial study, prior treatment did not affect 470 the urinary peptidomic profiles (19). As another limitation of our study, follow-up data were not accessible for all patients. Thus, correlation analysis of false positives cases 471 472 with later recurrences was not feasible. Therefore, no conclusion can be made on false-473 positives of BC-116 and BC-106 biomarker panels since they could be attributed to 474 early detection of subclinical recurrence that could not be detected by cystoscopy. This 475 has been previously described for other FDA-approved urinary biomarkers (37). 476 Furthermore, no investigations were performed in patients that had a positive test but a negative cystoscopy to rule out the presence of upper tract tumors. 477

Collectively, this prospective study provides evidence on the clinical relevance of the BC-116 and BC-106 biomarker classifiers for BC screening and monitoring. As supported by the presented results, such non-invasive biomarker panels can facilitate BC diagnosis (BC-116) and can be applied as adjuncts to cystoscopy in combination with cytology (BC-106) to reduce the number of follow-up cystoscopies as well as patient discomfort and financial burden.

484

485 Acknowledgments

This work was supported in part by BioMedBC (752755; H2020-MSCA-IF-2016), funded by the European Commission.

- 488 489 490 491 492 493 494 495 496
- 497

It is made available under a CC-BY-NC-ND 4.0 International license .

498

499 **References**

- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer
 2010;127(12):2893-917 doi 10.1002/ijc.25516.
- 5032.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global504Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide505for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 2021;71(3):209-49506doi 10.3322/caac.21660.
- 3. ACS. Cancer Facts & Figures 2014. Atlanta, GA, USA: American Cancer Society; 2014.
- 508
 4.
 Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. Bladder

 509
 cancer. Lancet 2016;388(10061):2796-810 doi 10.1016/S0140-6736(16)30512-8.
- Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. European urology 2019;76(5):639-57 doi 10.1016/j.eururo.2019.08.016.
- Maas M, Bedke J, Stenzl A, Todenhofer T. Can urinary biomarkers replace cystoscopy?
 World journal of urology 2019;37(9):1741-9 doi 10.1007/s00345-018-2505-2.
- 516
 7.
 Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374(9685):239-49

 517
 doi 10.1016/S0140-6736(09)60491-8.
- Ribal MJ, Cornford P, Briganti A, Knoll T, Gravas S, Babjuk M, *et al.* European Association of Urology Guidelines Office Rapid Reaction Group: An Organisationwide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. European urology 2020;78(1):21-8 doi 10.1016/j.eururo.2020.04.056.
- 5239.Freifeld Y, Lotan Y. Effect of blue-light cystoscopy on contemporary performance of
urine cytology. BJU international **2019**;124(2):251-7 doi 10.1111/bju.14574.
- 52510.Christensen E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, van der Keur K, van526Kessel K, et al. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for527Disease Surveillance in Bladder Cancer. European urology **2017**;71(6):961-9 doi52810.1016/j.eururo.2016.12.016.
- 529 11. Chakraborty A, Dasari S, Long W, Mohan C. Urine protein biomarkers for the
 530 detection, surveillance, and treatment response prediction of bladder cancer.
 531 American journal of cancer research 2019;9(6):1104-17.
- Siwy J, Mullen W, Golovko I, Franke J, Zurbig P. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clinical applications 2011;5(5-6):367-74 doi 10.1002/prca.201000155.
- Latosinska A, Siwy J, Mischak H, Frantzi M. Peptidomics and proteomics based on CEMS as a robust tool in clinical application: The past, the present, and the future.
 Electrophoresis 2019;40(18-19):2294-308 doi 10.1002/elps.201900091.
- 53814.Klein J, Papadopoulos T, Mischak H, Mullen W. Comparison of CE-MS/MS and LC-539MS/MS sequencing demonstrates significant complementarity in natural peptide540identification in human urine. Electrophoresis **2014**;35(7):1060-4 doi54110.1002/elps.201300327.
- 54215.Dakna M, He Z, Yu WC, Mischak H, Kolch W. Technical, bioinformatical and statistical543aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary544electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical545assessment. Journal of chromatography B, Analytical technologies in the biomedical546and life sciences 2009;877(13):1250-8 doi 10.1016/j.jchromb.2008.10.048.
- 54716.Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and548validation of new protein biomarkers for urothelial cancer: a prospective analysis. The549Lancet Oncology 2006;7(3):230-40 doi 10.1016/S1470-2045(06)70584-8.
- 550 17. Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, *et al.* 551 Prediction of muscle-invasive bladder cancer using urinary proteomics. Clinical

552 553		cancer research : an official journal of the American Association for Cancer Research 2009 ;15(15):4935-43 doi 10.1158/1078-0432.CCR-09-0226.
554	18.	Frantzi M, Vlahou A. Ten Years of Proteomics in Bladder Cancer: Progress and Future
555		Directions. Bladder cancer 2017 ;3(1):1-18 doi 10.3233/BLC-160073.
556	19.	Frantzi M, van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, et al.
557		Development and Validation of Urine-based Peptide Biomarker Panels for Detecting
558		Bladder Cancer in a Multi-center Study. Clinical cancer research : an official journal
559		of the American Association for Cancer Research 2016;22(16):4077-86 doi
560		10.1158/1078-0432.ccr-15-2715.
561	20.	Krochmal M, van Kessel KEM, Zwarthoff EC, Belczacka I, Pejchinovski M, Vlahou A, et
562		al. Urinary peptide panel for prognostic assessment of bladder cancer relapse.
563		Scientific reports 2019 ;9(1):7635 doi 10.1038/s41598-019-44129-y.
564	21.	Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO
565		Classification of Tumours of the Urinary System and Male Genital Organs-Part B:
566		Prostate and Bladder Tumours. European urology 2016;70(1):106-19 doi
567		10.1016/j.eururo.2016.02.028.
568	22.	Brierley JD, Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of
569		Malignant Tumours. Chicester: John Wiley & Sons, Incorporated; 2016. 1 online
570		resource (274 pages) p.
571	23.	Babjuk M, Burger M, Compérat E, Gontero P, Mostafid AH, Palou J, et al. EAU
572		Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). EAU Guidelines
573		Office, Arnhem, The Netherlands.; 2018.
574	24.	Argilés À, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, et al. CKD273, a New
575		Proteomics Classifier Assessing CKD and Its Prognosis. PLOS ONE 2013;8(5):e62837 doi
576		10.1371/journal.pone.0062837.
577	25.	Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, et al. Mass spectrometry for
578	20.	the detection of differentially expressed proteins: a comparison of surface-enhanced
579		laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid
580		communications in mass spectrometry : RCM 2004 ;18(2):149-56 doi 10.1002/rcm.1294.
581	26.	Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, et al. Quantitative
582	20.	urinary proteome analysis for biomarker evaluation in chronic kidney disease. Journal
583		of proteome research 2009 ;8(1):268-81 doi 10.1021/pr800401m.
584	27.	Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, <i>et al.</i> CE-MS analysis
585	27.	of the human urinary proteome for biomarker discovery and disease diagnostics.
586		Proteomics Clinical applications 2008 ;2(7-8):964 doi 10.1002/prca.200800024.
	20	
587	28.	DeLeo JM. Receiver operating characteristic laboratory (ROCLAB): Software for
588		developing decision strategies that account for uncertainty. Uncertainty Modeling
589	20	and Analysis, 1993 Proceedings, Second International Symposium on 1993 :318-25.
590	29.	Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: A review
591		of the current landscape and future directions. Urologic oncology 2021;39(1):41-51
592		doi 10.1016/j.urolonc.2020.08.016.
593	30.	Soria F, Droller MJ, Lotan Y, Gontero P, D'Andrea D, Gust KM, et al. An up-to-date
594		catalog of available urinary biomarkers for the surveillance of non-muscle invasive
595		bladder cancer. World journal of urology 2018 ;36(12):1981-95 doi 10.1007/s00345-018-
596		2380-x.
597	31.	Frantzi M, Latosinska A, Belczacka I, Mischak H. Urinary proteomic biomarkers in
598		oncology: ready for implementation? Expert review of proteomics 2019;16(1):49-63
599		doi 10.1080/14789450.2018.1547193.
600	32.	Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, et al. Evaluation of
601		Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.
602		European urology 2019 ;76(2):238-43 doi 10.1016/j.eururo.2019.04.035.
603	33.	van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo
604		CCM, Baixauli M, et al. Urine cell-based DNA methylation classifier for monitoring
605		bladder cancer. Clinical epigenetics 2018 ;10:71 doi 10.1186/s13148-018-0496-x.
606	34.	Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III,
607		multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white

It is made available under a CC-BY-NC-ND 4.0 International license .

608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623	35. 36. 37.	light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. The Journal of urology 2007 ;178(1):62-7 doi 10.1016/j.juro.2007.03.034. Wang Z, Que H, Suo C, Han Z, Tao J, Huang Z, <i>et al.</i> Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta- analysis. Oncotarget 2017 ;8(59):100648-56 doi 10.18632/oncotarget.22065. Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer cytopathology 2013 ;121(10):591-7 doi 10.1002/cncy.21327. Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, <i>et al.</i> Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. American journal of clinical pathology 2007 ;127(2):295-301 doi 10.1309/ADJL7E810U1H42BJ.
624		
625		
626		
627		
628		
629		
630		
631		
632		
633		
634		
635		
636		
637		
638		
639		
640		
641		
642		
643		
644		
645		
646		

647 **Table 1.** Clinical and demographical characteristics of the patients screened for primary

- 648 (Study Arm I) and recurrence BC (Study Arm II).
- 649
- 650

	Number of recruited patients
Study Arm I: Evaluation of nomogram for detecting Primary E	3C 73
Primary BC patients (%)	27 (37.0)
Urological controls (%)	46 (63.0)
Median Age (IQR)	66 (16.5)
Gender (M/F; %)	52 M (71.2) / 21 F (28.8)
Stage classification (TNM) for primary BC*	
■ Ta (%)	14 (51.9)
■ T1 (%)	6 (22.2)
■ T3 (%)	1 (3.7)
■ Tis (%)	1 (3.7)
■ Tx (%)	5 (18.5)
Grade classification for primary BC*	- ()
■ Low grade (%)	14 (51.9)
 High Grade (%) 	10 (37.0)
■ Gx (%)	3 (11.1)
Risk assessment for primary BC*	0 (111)
 High risk (%) 	11 (40.7)
 Low risk (%) 	15 (55.6)
 Unknown (%) 	1 (3.7)
Concomitant Tis (Yes/ No/ Unknown)	3 (11.1) / 13 (48.2) / 11 (40.7)
Cytology (Positive / Negative / NA)	14 (19.2) / 44 (60.3) / 15 (20.5)
Study Arm II: Evaluation of nomogram for detecting recurrer	
Positive for recurrent BC (%)	83 (17.4)
Negative for recurrence (%)	395 (82.6)
Median Age (IQR)	71 (15)
Gender (M/F; %)	381 M (79.7) / 97 F (20.3)
Stage classification (TNM) for recurrent BC*	
 Ta (%) T4 (%) 	58 (69.9)
 T1 (%) T0 (%) 	11 (13.6)
 T2 (%) T4 (%) 	3 (3.6)
 T4 (%) 	1 (1.2)
• Tis (%)	10 (12.0)
Grade classification for recurrent BC*	
 Low grade (%) 	55 (62.3)
 High Grade (%) 	25 (30.1)
• Gx (%)	3 (3.6)
Risk assessment for recurrent BC*	
 High risk (%) 	30 (36.1)
 Intermediate risk (%) 	27 (32.5)
 Low risk (%) 	25 (30.1)
 Unknown (%) 	1 (1.2)
 Cytology (Positive / Negative / Atypia / NA) 	33 (6.9) / 285 (59.6) / 19 (4.0) / 141 (29.
Excluded patients because of comorbidities	18
Excluded patients as TURB-T was not available to confirm cy	vstoscopy 33
Total number of recruited patients	602


It is made available under a CC-BY-NC-ND 4.0 International license .

651 652 653 654 655 656	Abbreviations: BC: bladder cancer; F: female; IQR: interquartile range; M: male; NA: not available; TNM: tumor, node, metastasis; Tis: carcinoma in situ; TURB-T: Transurethral resection of bladder tumor. *Tumor grade and stage were determined according to WHO criteria (21) and TNM classification (22), while the BC tumors were classified according to their risk of recurrence and progression into high, intermediate, or low risk based on the EAU guidelines published in 2018 (23).
657	
658	
659	
660	
661	
662	
663	
664	
665	
666	
667	
668	
669	
670	
671	
672	
673	
674	
675	
676	
677	
678	
679	
680	
681	
682	
683	
684	
685	

It is made available under a CC-BY-NC-ND 4.0 International license .

686 **Figures**

687




688

689

690

691

Figure 1. Schematic representation of the study workflow. Patients with primary BC, 692 693 recurrent BC and urological controls were enrolled at two different clinical centers (Hospital Clinic of Barcelona and Radboud University Medical Center). Patients 694 695 encountering other comorbidities were excluded from this study (n=18). A total number 696 of 584 participants were considered for further analysis and stratified into two cohorts. 697 The primary cohort was consisted of patients with primary BC (n=73) whereas the 698 recurrent cohort comprised of patients with BC recurrences (n=83) and those negative for recurrence controls (n=395). Abbreviations: BC: bladder cancer; UTUC: Upper 699 tract urothelial carcinoma; PC; pancreatic cancer; PCa: prostate cancer; RCC: renal cell 700 701 carcinoma: **TURBT**: trans urethral resection of bladder tumor.



It is made available under a CC-BY-NC-ND 4.0 International license .


725


Figure 2. A, ROC curve analysis for the urinary biomarker panel BC-116 performed in 726 727 the primary cohort. The AUC, 95% CI, and P value for the classification of the BC 728 patients are also provided in the table shown in Panel A. B-D, Classification scores 729 presented in Box-and-Whisker displaying the level of discrimination between B) the 730 urothelial BC cases and the urologic controls, C) BC cases and controls according to their TNM stage, and D) BC cases and controls considering their grade. The average 731 rank differences were significantly different (****P≤ 0.0001 and *P<0.05) as defined with 732 733 Kruskal-Wallis H test.

734

735

It is made available under a CC-BY-NC-ND 4.0 International license .





ROC curve	BC-116	Cytology
Primary cohort	n=58	n=58
Cases / Controls	n= 26 / 32	n= 26 / 32
AUC	0.84	0.68
95% CI	0.72-0.92	0.55-0.80
Significance P	<0.0001	0.0008
Pairwise comparison P = 0.0195		


ROC curve	BC-116 & Cytology
Primary cohort	n=58
Cases / Controls	n= 26 / 32
AUC	0.85
95% CI	0.73 – 0.93
Significance P	<0.0001

740 Figure 3.

A, ROC curves for the urinary BC-116 biomarker panel and the cytology as performed
to those patients from the primary cohort with available cytological data. B, ROC curve
for the integrative nomogram including the BC-116 biomarker panel and the cytology.
The AUCs, 95% Cis, and P values are provided in the respective tables.

It is made available under a CC-BY-NC-ND 4.0 International license .





- 756
- 757

758

759

760

761 Figure 4.


A, ROC curve for the BC-106 urinary biomarker panel, consisting of 106 peptides as performed in the recurrent cohort. **B**, ROC curve analysis for the urinary BC-106 biomarker panel as performed in those patients from the recurrence cohort with available cytological data. The AUCs, 95% Cis and P values are provided for the classification of recurrent BC patients.

- 767
- 768
- 769

770

- 771
- 772

It is made available under a CC-BY-NC-ND 4.0 International license .



774

775 **Figure 5.**

776 A, ROC curve analysis for the integrative nomogram including the urinary BC-106 biomarker panel and cytology, as performed in 318 patients (consisted of 36 positive 777 and 282 negative for recurrence controls) with available cytological data from the 778 779 recurrent cohort. The AUC, 95% CI, and P value for the integrative nomogram are provided in the table in panel A. B-D, Classification scores presented in Box-and-780 Whisker displaying the level of discrimination between **B**) the recurrence BC cases and 781 the negative for recurrence controls, C) the recurrence BC cases and the negative for 782 recurrence controls among stage, and **D**) the recurrence BC cases and the negative for 783 784 recurrence controls among grade groups. The average rank differences were significantly different ((**** $P \le 0.0001$ and *P = 0.05) as defined by Kruskal-Wallis H test. 785

It is made available under a CC-BY-NC-ND 4.0 International license .

786 Supplementary Files

787

Supplementary Table S1. Clinical and demographical data for the 73 samples from
 patients with primary BC.

- 790
- 791 Supplementary Table S2. Clinical and demographical data for the urine samples (n=
- 792 **478) from recurrent BC patients**.
- 793
- 794 **Supplementary Table S3.** List of scoring data for 73 patients with primary BC and 478
- 795 patients that were screened for recurrent BC.